Optimer Pharmaceuticals, Inc.
10110 Sorrento Valley Road
Suite C
San Diego,
CA 92121
United States - Map
Phone: 858-909-0736
Fax: 858-909-0737
Web Site: http://www.optimerpharma.com
| Optimer Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing anti-infective products worldwide. The company develops products that treat gastrointestinal infections and related diseases. Its two late-stage anti-infective product candidates include Fidaxomicin, the lead product candidate and an antibiotic that is in second Phase III registration trial for the treatment of clostridium difficile-infections; and Prulifloxacin, a prodrug in the fluoroquinolone class of antibiotics, which completed second Phase III trials for the treatment of infectious diarrhea in travelers. It also develops OP-1068/CEM-101, an antibiotic for the treatment of upper and lower respiratory tract infections; OPT-88, a disease-modifying intra-articular, or within the cavity of a joint, therapy for osteoarthritis; OPT-822, a carbohydrate-based cancer immunotherapy for the treatment of metastatic breast cancer; and an OPopS drug discovery platform. The company has a collaborative research and development, and license agreement with Cempra Pharmaceuticals, Inc. to discover, develop, and commercialize drugs based on macrolide and ketolide compounds. Optimer Pharmaceuticals was founded in 1998 and is based in San Diego, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Michael Chang PH.D., 59
Co-Founder, Chairman, Chief Exec. Officer and Pres |
$
534.00K |
$
0 | Mr. John D. Prunty CPA, 47
Chief Financial Officer, Principal Accounting Officer, VP of Fin. and Sec. |
$
317.00K |
$
0 | Dr. Tessie M. Che Ph.D, 59
Chief operating Officer and Sr. VP of Corp. Affairs |
$
330.00K |
$
0 | Mr. Kevin P. Poulos , 50
Chief Commercial Officer and VP of Marketing & Sales |
$
252.00K |
$
0 | Dr. Youe-Kong Shue Ph.D., 59
VP of Clinical Devel. |
$
276.00K |
$
0 |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.29% Nasdaq 
0.14 (1.21%) 
Profile
